Advertisement

Propionic Acid Animal Model of Autism

  • Sandy R. Shultz
  • Derrick F. MacFabe

Abstract

Autism spectrum disorders (ASD) are an increasing problem in Western society. Although largely genetic in nature, many environmental factors may play a role in triggering ASD in sensitive populations. Early antibiotic exposure, systemic immune and metabolic abnormalities, food cravings, and gastrointestinal comorbidities, which often relate to behavioral worsening, have been observed. Consequently, there is a growing need to develop animal models to examine how environmental factors relate to ASD pathogenesis. While growing evidence suggests that dietary or gut-related factors may influence brain function and symptomology in ASD patients, until recently no specific compounds have been identified which could provide a common explanation for the behavioral, biochemical, and neuropathological changes observed in ASD. This chapter will describe the recently developed propionic acid (PPA) rodent model of ASD and how its findings may relate to the clinical condition. PPA is a short-chain fatty acid that is endogenous to the human body as both an intermediary of fatty acid metabolism and a fermentation end product of antibiotic resistant enteric gut bacteria such as clostridia. Although largely derived in the gut, PPA and related short-chain fatty acids can readily gain access to the brain, where they can induce a diverse range of neurophysiological processes capable of altering both brain function and behavior. There are numerous lines of evidence suggesting that PPA and other enteric short-chain fatty acids may be elevated in ASD. To further examine the relationship between PPA and ASD, intracerebroventricular (ICV) injections of PPA in rats have recently been used as an animal model of ASD. Studies using this model have found that ICV treatment of PPA is capable of inducing numerous behavioral, electrophysiological, and neuropathological changes in rats that are consistent with those observed in ASD. Similar, but less pronounced, effects are also induced by ICV treatment of related gut short-chain fatty acids such as butyrate and sodium acetate. Together these findings suggest PPA and related short-chain fatty acids as putative risk factors for ASD and provide further evidence for a possible link between diet, metabolic, and/or gastrointestinal factors and ASD.

Keywords

Autism Spectrum Disorder Autism Spectrum Disorder Water Maze Intracellular Acidification Autism Spectrum Disorder Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Al-Lahham SH, Peppelenbosch MP, Roelofsen H, et al. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta. 2010;1801:1175–83.PubMedCrossRefGoogle Scholar
  2. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61:551–3.PubMedCrossRefGoogle Scholar
  3. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: a review and future directions. Int J Dev Neurosci. 2005;23:183–7.PubMedCrossRefGoogle Scholar
  4. Bell JG, MacKinlay EE, Dick JR, et al. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids. 2004;71:201–4.PubMedCrossRefGoogle Scholar
  5. Bergersen L, Rafiki A, Ottersen OP. Immunogold cytochemistry identifies specialized membrane domains for monocarboxylate transport in the central nervous system. Neurochem Res. 2002;27:89–96.PubMedCrossRefGoogle Scholar
  6. Bonnet U, Bingmann D, Wiemann M, et al. Intracellular pH modulates spontaneous and epileptiform bioelectric activity of hippocampal CA3-neurones. Eur Neuropsychopharmacol. 2000;10:97–103.PubMedCrossRefGoogle Scholar
  7. Borgstrom MK, Edwardsson S, Svensater G, et al. Acid formation in sucrose exposed dental plaque in relation to caries incidence in schoolchildren. Clin Oral Investig. 2000;4:9–12.PubMedCrossRefGoogle Scholar
  8. Brass EP, Beyerinck RA. Effects of propionate and carnitine on the hepatic oxidation of short- and medium-chain-length, fatty acids. Biochem J. 1988;250:819–25.PubMedGoogle Scholar
  9. Brass EP, Fennessey PV, Miller LV. Inhibition of oxidative metabolism by propionic acid and its reversal by carnitine in isolated rat hepatocytes. Biochem J. 1986;236:131–6.PubMedGoogle Scholar
  10. Brock M, Buckel W. On the mechanism of action of the antifungal agent propionate. Eur J Biochem. 2004;271:3227–41.PubMedCrossRefGoogle Scholar
  11. Bu B, Ashwood P, Harvey D, et al. Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukot Essent Fatty Acids. 2006;74:215–21.PubMedCrossRefGoogle Scholar
  12. Champeil-Potokar G, Chaumontet C, Guesnet P, et al. Docosahexaenoic acid (22:6n-3) enrichment of membrane phospholipids increases gap junction coupling capacity in cultured astrocytes. Eur J Neurosci. 2006;24:3084–90.PubMedCrossRefGoogle Scholar
  13. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13:171–81.PubMedCrossRefGoogle Scholar
  14. Clarke JT, Clark-Taylor BE. Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial beta oxidation by long chain acyl-CoA dehydrogenase. Med Hypotheses. 2004;62:970–5.CrossRefGoogle Scholar
  15. Clemente JC, Ursell LK, Parfrey LW, et al. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148:1258–70.PubMedCrossRefGoogle Scholar
  16. Coulter DL. Carnitine, valproate, and toxicity. J Child Neurol. 1991;6:7–14.PubMedCrossRefGoogle Scholar
  17. Dringen R. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal. 2005;7:1223–33.PubMedCrossRefGoogle Scholar
  18. Feliz B, Witt DR, Harris BT. Propionic acidemia: a neuropathology case report and review of prior cases. Arch Pathol Lab Med. 2003;127:325–8.Google Scholar
  19. Filipek PA, Juranek J, Nguyen MT, et al. Relative carnitine deficiency in autism. J Autism Dev Disord. 2004;34:615–23.PubMedCrossRefGoogle Scholar
  20. Finegold SM, Dowd SE, Gontcharova V, et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16:444–53.PubMedCrossRefGoogle Scholar
  21. Finegold SM, Downes J, Summanen PH. Microbiology of regressive autism. Anaerobe. 2012;18:260–2.PubMedCrossRefGoogle Scholar
  22. Gonzalez LE, Andrews N, File SE. 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res. 1996;732:145–53.PubMedCrossRefGoogle Scholar
  23. Hanstock TL, Clayton EH, Li KM, et al. Anxiety and aggression associated with the fermentation of carbohydrates in the hindgut of rats. Physiol Behav. 2004;82:357–68.PubMedCrossRefGoogle Scholar
  24. Herbert MR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol. 2010;23:103–10.PubMedCrossRefGoogle Scholar
  25. Horvath K, Papdimitriou JC, Rabsztyn A, et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135:559–63.PubMedCrossRefGoogle Scholar
  26. James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 2009;23:2374–83.PubMedCrossRefGoogle Scholar
  27. Jan G, Belzacq AS, Haouzi D, et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Differ. 2002;9:179–88.PubMedCrossRefGoogle Scholar
  28. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46:76–84.PubMedCrossRefGoogle Scholar
  29. Kalueff AV, Fox MA, Gallagher PS, et al. Hypolocomotion, anxiety, and serotonin syndrome-like behavior contribute to the complex of serotonin transporter knockout mice. Genes Brain Behav. 2007;6:389–400.PubMedCrossRefGoogle Scholar
  30. Karuri AR, Dobrowsky E, Tannock IF. Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment. Br J Cancer. 1993;68:1080–7.PubMedCrossRefGoogle Scholar
  31. Kidd PM. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev. 2007;12:207–27.PubMedGoogle Scholar
  32. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003;278:25481–9.PubMedCrossRefGoogle Scholar
  33. MacFabe DF, Cain DP, Rodriguez-Capote K, et al. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res. 2007;176:149–69.PubMedCrossRefGoogle Scholar
  34. MacFabe DF, Rodriguez-Capote K, Hoffman JE, et al. A novel rodent model of autism: intraventricular infusions of propionic acid increase locomotor activity and induce neuroinflammation and oxidative stress in discrete regions of adult rat brain. Am J Biochem Biotechnol. 2008;4:146–66.CrossRefGoogle Scholar
  35. MacFabe DF, Cain NE, Boon F, et al. Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: Relevance to autism spectrum disorder. Behav Brain Res. 2011;217:47–54.PubMedCrossRefGoogle Scholar
  36. Molloy CA, Morrow AL, Meinzen-Derr J, et al. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol. 2005;172:198–205.PubMedCrossRefGoogle Scholar
  37. Monks TJ, Ghersi-Egea JF, Philbert M, et al. Symposium overview: the role of glutathione in neuroprotection and neurotoxicity. Toxicol Sci. 1999;51:161–77.PubMedCrossRefGoogle Scholar
  38. Neuhaus E, Beauchaine TP, Bernier R, et al. Neurobiological correlates of social functioning in autism. Clin Psychol Rev. 2010;30:730–48.CrossRefGoogle Scholar
  39. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002;67:53–83.PubMedCrossRefGoogle Scholar
  40. Nyhan WL, Bay C, Beyer EW, et al. Neurologic nonmetabolic presentation of propionic acidemia. Arch Neurol. 1999;56:1143–7.PubMedCrossRefGoogle Scholar
  41. Pastural E, Ritchie S, Lu Y, et al. Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids. 2009;81:253–64.PubMedCrossRefGoogle Scholar
  42. Peinado A, Yuste R, Katz LC. Extensive dye coupling between rat neocortical neurons during the period of circuit formation. Neuron. 1993;10:103–14.PubMedCrossRefGoogle Scholar
  43. Puwanant M, Mo-Suwan L, Patrapinyokul S. Recurrent d-lactic acidosis in a child with short bowel syndrome. Asia Pac J Clin Nutr. 2005;14:195–8.PubMedGoogle Scholar
  44. Rafiki A, Boulland JL, Halestrap AP, et al. Highly differential expression of the monocarboxylate transporters MCT2 and MCT4 in the developing rat brain. Neuroscience. 2003;122:677–88.PubMedCrossRefGoogle Scholar
  45. Richardson AJ. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids. 2004;70:383–90.PubMedCrossRefGoogle Scholar
  46. Rinehart NJ, Tonge BJ, Iansek R, et al. Gait function in newly diagnosed children with autism: cerebellar and basal-ganglia related motor disorder. Dev Med Child Neurol. 2006;48:819–24.PubMedCrossRefGoogle Scholar
  47. Roe RC, Millington DS, Maltby DA, et al. L-carnitine enhances excretion of propionyl coenzyme A as propionylcarnitine in propionic acidemia. J Clin Invest. 1984;73:1785–8.PubMedCrossRefGoogle Scholar
  48. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17:290–314.PubMedCrossRefGoogle Scholar
  49. Sasson NJ, Turner-Brown LM, Holtzclaw TN, et al. Children with autism demonstrate circumscribed attention during passive viewing of complex social and nonsocial picture arrays. Autism Res. 2008;1:31–42.PubMedCrossRefGoogle Scholar
  50. Shah P, Nankova BB, Parab S, et al. Short chain fatty acids induce TH gene expression via ERK-dependent phosphorylation of CREB protein. Brain Res. 2006;1107:13–23.PubMedCrossRefGoogle Scholar
  51. Shultz SR, MacFabe D, Ossenkopp K-P, et al. Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic end-product, impairs social behavior in the rat: implications for an animal model of autism. Neuropharmacology. 2008;54:901–11.PubMedCrossRefGoogle Scholar
  52. Shultz SR, MacFabe DF, Martin S, et al. Intracerebroventricular injections of the enteric bacterial metabolic product propionic acid impair cognition and sensorimotor ability in the Long-Evans rat: further development of a rodent model of autism. Behav Brain Res. 2009;200:33–41.PubMedCrossRefGoogle Scholar
  53. Song Y, Liu C, Finegold SM. Real-time PCR quantification of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70:6459–65.PubMedCrossRefGoogle Scholar
  54. Stackebrandt E, Rainey FA. Phylogenetic relationships. In: Rood JI, McClane BA, Songer JG, Titball RW, editors. The Clostridia, molecular biology and pathogenesis. Academic Press; 1997. pp. 3–19.Google Scholar
  55. Tamai I, Takanaga H, Maeda H, et al. Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem Biophys Res Commun. 1995;214:482–9.PubMedCrossRefGoogle Scholar
  56. Thomas RH, Foley KA, Mepham JR, et al. Altered brain phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a potential model of autism spectrum disorders. J Neurochem. 2010;113:515–29.PubMedCrossRefGoogle Scholar
  57. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001;65:1–7.PubMedCrossRefGoogle Scholar
  58. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81.PubMedCrossRefGoogle Scholar
  59. Wajner M, Latini A, Wyse AT, et al. The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J Inherit Metab Dis. 2004;27:427–48.PubMedCrossRefGoogle Scholar
  60. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br J Pharmacol. 2007;150:963–76.PubMedCrossRefGoogle Scholar
  61. Wiest MM, German JB, Harvey DJ, et al. Plasma fatty acid profiles in autism: a case-control study. Prostaglandins Leukot Essent Fatty Acids. 2009;80:221–7.PubMedCrossRefGoogle Scholar
  62. Williams TA, Mars AE, Buyske SG, et al. Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. Arch Pediatr Adolesc Med. 2007;161:356–61.PubMedGoogle Scholar
  63. Williams BL, Hornig M, Buie T, et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS One. 2011;6:e24585.PubMedCrossRefGoogle Scholar
  64. Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp Dermatol. 2005;14:143–152.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Medicine, Royal Melbourne HospitalThe University of Melbourne, Melbourne Brain CentreParkvilleAustralia
  2. 2.Departments of Psychology and Psychiatry and Division of Developmental DisabilitiesUniversity of Western Ontario, The Kilee Patchell-Evans Autism Research GroupLondonCanada

Personalised recommendations